


Amendment to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of Claims:


1. (Currently amended) A pharmaceutical composition comprising the S-isomer of ~~a metabolite of ketotifen,~~ and a compound having the structure:



where R is H, and pharmaceutically acceptable salts and solvates thereof, together with a pharmaceutically acceptable carrier, said composition being free of sedative side effects and being substantially free of the corresponding R-isomer.

2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)

6. (Previously presented) A method for synthesis of the stereochemically active compounds of the structure:



wherein R is H, being of the R- or S-configuration, comprising the conversion of the corresponding stereochemical isomers of ketotifen into their 1-(2,2,2-trichloro ethoxycarbonyl) nor-intermediates, followed by Cd/Pb-catalyzed cleavage to the final products S-norketotifen or R-norketotifen.

7. (Currently amended) A method for treating a disease selected from the group consisting of allergic disorders against which ketotifen has therapeutic activity, ~~and~~ dermal disorders

against which ketotifen has therapeutic activity, bronchial disorders against which ketotifen has therapeutic activity, pulmonary disorders against which ketotifen has therapeutic activity, and gastroenterological disorders against which ketotifen has therapeutic activity, which comprises administering to a mammal in need thereof a therapeutically effective amount of the S-isomer of norketotifen or a pharmaceutically acceptable salt or solvate thereof, substantially free of the corresponding R-isomer, while eliminating the dose-limiting sedative side effects of ketotifen.

8. (Previously presented) The method of claim 7, wherein said bronchial or pulmonary disorder is selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, cough, bronchitis and bronchial hyperreactivity.

9. (Currently amended) The method of claim 7, wherein said allergic disorder is selected from the group consisting of allergic rhinitis, ~~urticaria,~~ and allergic conjunctivitis.

10. (Previously presented) The method of claim 7, wherein said dermal disorder is selected from the group consisting of atopic dermatitis, urticaria, and psoriasis.

11. (Cancelled)

12. (Cancelled)

13. (Previously presented) The method of claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered by inhalation or by nasal,

parenteral, topical, dermal, transdermal, rectal, sublingual, conjunctival or oral administration.

14. (Original) The method according to claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered orally.

15. (Original) The method according to claim 7, wherein the therapeutically active compound or a pharmaceutically acceptable salt or solvate thereof is administered orally in an extended release formulation.

16. (cancelled)


17. (cancelled)

18. (Original) The method according to claim 7, wherein the amount of the therapeutically active compound is administered from about 0.5 mg to about 200 mg, one to four times per day.

19. (Original) The method according to claim 7, wherein a solid, semi-solid, liquid, suspension, aerosol or topical or transdermal pharmaceutical composition, comprising a therapeutically effective amount of the therapeutically active compound, or a pharmaceutically acceptable salt or solvate thereof, is administered in combination with a pharmaceutically acceptable carrier or carrier system.


20. (Cancelled)

21. (Currently amended) A synthetically produced substantially optically pure form of the S-isomer of a compound of the structure:



where R is H.

22. (New) A pharmaceutical composition comprising the S-isomer of a compound having the structure:



where R is H, and pharmaceutically acceptable salts and solvates thereof, together with a pharmaceutically acceptable carrier, wherein said compound has an optical purity of at least 95% ee.